The content on this site is intended for healthcare professionals only
The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC
Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC
Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer
Administering systemic chemotherapy improves survival for patients with resectable CRCLM
